No Data
No Data
Scinai Immunotherapeutics Delays Annual Report Filing
Top Midday Decliners
Scinai Immunotherapeutics Signs An Option Agreement To Acquire Rare Disease Company Pincell And Its Novel Antibody For Treating Severe Dermatological Conditions; No Financial Terms Of Transaction Disclosed; Files An Application For €12 Million Grant...
Scinai Signs An Option Agreement To Acquire Rare Disease Company Pincell And Its Novel Antibody For Treating Severe Dermatological Conditions >SCNI
Scinai Signs $10M Standby Equity Agreement, Retains Control Over Stock Sales to Yorkville
Press Release: SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT